Ontology highlight
ABSTRACT: Objective
This study aimed to compare assessments between Beneluxa Initiative member countries' assessments and identify alignments and divergences.Methods
A retrospective comparative analysis was performed that investigated (i) number and type of assessed indications (for Austria (AT), Belgium (BE), Ireland (IE), and the Netherlands (NL)); (ii) added benefit conclusions (for BE, IE, and NL); and (iii) the main arguments underlying differences in conclusions (for BE, IE, and NL). Data were retrieved directly from agency representatives and from public HTA reports. European Medicines Agency approved indications were included for drugs assessed between 2016 and 2020, excluding veterinary drugs, generics, and biosimilars.Results
Only 44 (10 percent) of the 444 included
SUBMITTER: Vreman RA
PROVIDER: S-EPMC11570237 | biostudies-literature | 2023 Jun
REPOSITORIES: biostudies-literature